Dr Lal PathLabs Limited completed the acquisition of a stake in SN Genelab Private Limited on October 1, 2026. The transaction was executed in accordance with the terms and conditions of the agreement.

This completion follows the Board of Directors' approval of the acquisition, which was previously intimated to stock exchanges on September 24, 2026. The company confirmed that all disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have been duly made.

Regulatory compliance and disclosure

The company filed the update with both the National Stock Exchange of India Limited and BSE Limited. The filing references SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time. The Company Secretary and Compliance Officer, Vinay Gujral, signed the digital submission confirming the completion of the said acquisition.

Dr Lal PathLabs Limited announced on September 26, 2026, that its step-down subsidiary, Dr Lal PathLabs FZCO (DLPL Dubai), has completed the acquisition of an 80% stake in Sunshine Healthcare Limited (SHL) based in Ghana. This move solidifies the company's presence in the African diagnostic market.

The completion follows the earlier board approval by DLPL Dubai, a wholly owned subsidiary of Dr Lal PathLabs, which was intimated to stock exchanges on July 24, 2026. With this transaction finalized, SHL now operates as a step-down subsidiary of the Indian diagnostic chain.

Regulatory compliance and disclosures

The company stated that all mandatory disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, were duly completed. These disclosures were aligned with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time.

The acquisition was executed in accordance with the agreement and prevailing provisions applicable in Ghana. Dr Lal PathLabs requested both the National Stock Exchange of India Limited and BSE Limited to take the completion details on record.

Strategic footprint expansion

This acquisition represents a significant step in Dr Lal PathLabs' international growth strategy, particularly within the West African region. By securing a majority stake in Sunshine Healthcare Limited, the company gains substantial control over local operations and market access.

The transaction highlights the company's continued focus on expanding its global diagnostic network through strategic acquisitions.